Dermatology: from the daily briefing

Every daily briefing item tagged dermatology, newest first. The weekly roundup is on the dermatology page.

• Nov 11, 2026Neoantigen therapy plus pembrolizumab raises 24-month recurrence-free survival to 82.2% from 70.0% in melanomaEvidence
• Nov 11, 2026Ixekizumab plus tirzepatide beats ixekizumab alone at 52 weeks in psoriatic arthritis with obesityEvidence
• Nov 10, 2026Phase 2 trial of brepocitinib, an oral TYK2 and JAK1 inhibitor, reports improvement in cutaneous sarcoidosisEvidence
• Nov 10, 2026Topical sirolimus gel reaches treatment success in 72.4% versus 33.3% with placebo for hyperplastic rosaceaEvidence
• Nov 9, 2026Zura Bio ends its tibulizumab hidradenitis suppurativa program after a phase 2 missEvidence
• Nov 7, 2026J&J says 58% of psoriatic arthritis patients on oral icotrokinra reached ACR20 at week 16 in phase 3 dataEvidence
• Nov 3, 2026In atopic dermatitis, H1 antihistamines did not give a clinically important reduction in itch or disease severityEvidence
• Nov 3, 2026StimLabs launches DermaForm, a 510(k)-cleared particulate collagen scaffold for acute and chronic woundsDeployment
• Nov 2, 2026InventisBio reports phase 3 TYK2 inhibitor results in psoriasisEvidence
• Nov 2, 2026Oral povorcitinib meets 52-week facial repigmentation endpoint in two phase 3 vitiligo trialsEvidence
• Oct 30, 2026FDA classifies software-aided adjunctive devices physicians use on lesions suspicious for skin cancer into class IIRegulation
• Oct 30, 2026FDA approves tildrakizumab (Ilumya) for adults with active psoriatic arthritisRegulation
• Oct 29, 2026Adding efgartigimod to prednisone fails to improve remission or cut steroid use in pemphigusEvidence